Influence of glucose concentration on the effects of aspirin, ticlopidine and clopidogrel on platelet function and platelet-subendothelium interaction

被引:18
作者
De La Cruz, JP
Arrebola, MM
Villalobos, MA
Pinacho, A
Guerrero, A
González-Correa, JA
de la Cuesta, FS
机构
[1] Univ Malaga, Sch Med, Dept Pharmacol & Therapeut, E-29071 Malaga, Spain
[2] Univ Malaga, Sch Med, Dept Human Anat, E-29071 Malaga, Spain
关键词
aspirin; ticlopidine; clopidogrel; platelet; nitric oxide (NO); platelet-subendothelium interaction;
D O I
10.1016/j.ejphar.2003.10.055
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Clinical studies have shown that the ability of aspirin to prevent cerebrovascular accidents is weaker in patients with diabetes. The aim of this study was to determine whether high concentrations of glucose modified the effect of aspirin, ticlopidine and clopigodrel on platelet function and platelet-subendothelium interactions. This in vitro study tested three different concentrations of glucose. The effects were analyzed by comparing platelet aggregometry in whole blood, nitric oxide and prostacyclin production in cultures of human endothelial cells, and by quantitative analysis of morphological features of the platelet-subendothelium interaction under flow conditions. High concentrations of glucose increased platelet aggregation (13.9 Omega with 5 mM glucose vs. 21.6 Omega with 16.6 mM) and platelet-subendothelium interactions (28.9% with 5 mM glucose vs.35.2% with 16.6 mM), and decreased nitric oxide and prostacyclin production. In the presence of high concentrations of glucose, the antiaggregant effect of aspirin and its influence on nitric oxide production were diminished (IC50 54 muM with 5 mM glucose vs.556 muM with 16.6 mM glucose), and its effect on the platelet-subendothelium interaction was reduced (10.5% platelet occupancy with 5 mM glucose vs.23% with 16.6 mM glucose). The effects of ticlopidine and clopidogrel were not significantly modified. (C) 2003 Elsevier B.V All rights reserved.
引用
收藏
页码:19 / 27
页数:9
相关论文
共 46 条
[1]  
Amado Senars J A, 1981, Sangre (Barc), V26, P409
[2]  
ARREBOLA MM, IN PRESS J CARDIOVAS
[3]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[4]   ELECTRONIC AGGREGOMETER - NOVEL DEVICE FOR ASSESSING PLATELET BEHAVIOR IN BLOOD [J].
CARDINAL, DC ;
FLOWER, RJ .
JOURNAL OF PHARMACOLOGICAL METHODS, 1980, 3 (02) :135-158
[5]  
Chakrabarti S, 2000, DIABETES-METAB RES, V16, P393, DOI 10.1002/1520-7560(0000)9999:9999<::AID-DMRR157>3.0.CO
[6]  
2-G
[7]   THROMBOXANE BIOSYNTHESIS AND PLATELET-FUNCTION IN TYPE-II DIABETES-MELLITUS [J].
DAVI, G ;
CATALANO, I ;
AVERNA, M ;
NOTARBARTOLO, A ;
STRANO, A ;
CIABATTONI, G ;
PATRONO, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (25) :1769-1774
[8]   Nitric oxide-cGMP and prostacyclin-cAMP pathways in patients with type II diabetes and different types of retinopathy [J].
De La Cruz, JP ;
Moreno, A ;
Guerrero, A ;
Ortega, G ;
González-Correa, JA ;
de la Cuesta, FS .
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2002, 32 (01) :25-32
[9]   Influence of nitric oxide on the in vitro antiaggregant effect of ticlopidine [J].
De la Cruz, JP ;
Arrebola, MM ;
Guerrero, A ;
de la Cuesta, FS .
VASCULAR PHARMACOLOGY, 2002, 38 (03) :183-186
[10]   Effect of aspirin on prostanoids and nitric oxide production in streptozotocin-diabetic rats with ischemic retinopathy [J].
De La Cruz, JP ;
Guerrero, A ;
Paniego, MJ ;
Arranz, I ;
Moreno, A ;
de la Cuesta, FS .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 (02) :96-101